Ruxolitinib Krka (ruxolitinib)

Where it stands

Ruxolitinib Krka (ruxolitinib), from KRKA tovarna zdravil d.d. Novo mesto, received a CHMP positive opinion on 2026-11-12 for the EU. The records show its status as "Opinion" and give no approval date, so it is not yet authorised. The European Commission (EC) has still to adopt its decision.

The proposed indications are myelofibrosis (MF) and polycythaemia vera (PV) in adults, and graft versus host disease (GvHD) in adults and children. The records list the therapeutic areas as primary myelofibrosis, polycythaemia vera and GvHD.

The only forward-looking date is an estimated EC decision on 2027-01-18. It is calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. It is not an official date and should be treated as a planning assumption.

Regulatory pathway and designations

The only designation recorded is "Generic". In the EU, a generic product relies on the data package of an already authorised reference medicine. It typically shows pharmaceutical quality and bioequivalence rather than repeating the full clinical programme. The records do not name the reference medicine or the legal basis, so those details cannot be confirmed here.

Other EU authorisations for the same substance are Jakavi, Ruxolitinib Zentiva, Ruxolitinib Viatris and Opzelura. Jakafi Xr is listed as approved in the US. The records give no formulation, strength or indication details for these products. They therefore do not show how closely Ruxolitinib Krka matches any of them.

After a positive CHMP opinion, the EC normally issues a decision, usually within about 67 days. Only then is the product authorised across the EU. The records show the CHMP step as complete and the EC step as pending.

Safety and pharmacovigilance

The records contain no safety, risk management plan or pharmacovigilance information for this product, so no assessment can be made from them.

What to watch

The first milestone is the EC decision, estimated for 2027-01-18. An actual decision earlier or later than that estimate would not be unusual, because the date is a calculation rather than a scheduled event. The records show no approval date yet.

Once the decision is published, the final product information will show the authorised indications. The records describe the proposed indications as MF, PV and GvHD, so check that the authorised wording matches. The market launch timing is not covered in the records.

The EU already has several authorised ruxolitinib products, including other generic-named ones such as Ruxolitinib Zentiva and Ruxolitinib Viatris. Ruxolitinib Krka would be another entrant. The records provide no information on pricing, reimbursement or market share, so none is assumed here.